Document ID: chunk:federal_register_of_legislation:F2006L02853:body:0:p5
Version: federal_register_of_legislation:F2006L02853
Segment Type: other
Provision Reference: 
Character Range: 12155–15571

commercialisation strategies; and

           (g) the facilities, capabilities and expertise brought about through partnerships and collaborations.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence to support their claims under this merit criterion.

    Criterion 2: Scope and Nature of Partnerships and Collaborations

    The Board/Committee will assess whether each applicant has established, or proposes to establish, an appropriate range of R&D partnerships and collaborations between themselves and research and medical institutions, biotechnology companies, local or global pharmaceuticals companies and pharmaceutical service providers, and the nature of those partnerships and collaborations.

    The Board/Committee will consider the extent to which the applicant's existing and proposed partnerships and collaborations contribute to the applicant's business strategy, and benefit the Australian industry overall, such as through the transfer of skills and technology; the development of infrastructure and/or co-location of partners; and the generation and sharing of intellectual property and/or royalties.

    In relation to partnerships and collaborations that are proposed or still to be finalised, applicants must provide in their application evidence of the intended partnership or collaboration.  This may include letters of intent, draft agreements or memoranda of understanding from potential partners or collaborators describing the nature, timing and scope of the arrangements.

    In respect of this merit criterion, applicants could address the following factors:

            (a) the number, value and form of existing R&D partnerships and collaborations (including contractual arrangements and joint venture partnerships);

            (b) the quality of R&D partners – their capabilities and track record;

            (c) the extent to which the applicant proposes to extend existing, or forge new, R&D partnerships and linkages;

            (d) how the existing and proposed partnerships and collaborations contribute to the applicant's business strategy;

            (e)  the extent that partnerships will result in the development of infrastructure and/or co-location of partners in Australia, the sharing of intellectual property and/or royalties, and the sharing and/or transfer of skills and technology in Australia; and

            (f) how the applicant proposes to utilise and add value to the Australian Government's investment in health and medical research.

    These factors should not be considered exhaustive nor will they all be applicable to all applicants.  Applicants are also welcome to provide further relevant evidence to support their claims under this merit criterion.

    Criterion 3: Technical Merit of the Proposed Activities

    The Board/Committee will assess whether the eligible Australian pharmaceutical R&D activities proposed by each applicant are of high technical merit.

    In respect of this merit criterion, applicants could address the following factors:

            (a) the extent to which the proposed activities involve leading edge technologies, techniques or skills;

            (b) the degree of innovation evident in the proposed activities;

            (c) whether the proposed activities include activity